220 related articles for article (PubMed ID: 34204736)
1. The Olfactory Receptor Gene Product, OR5H2, Modulates Endometrial Cancer Cells Proliferation via Interaction with the IGF1 Signaling Pathway.
Shibel R; Sarfstein R; Nagaraj K; Lapkina-Gendler L; Laron Z; Dixit M; Yakar S; Werner H
Cells; 2021 Jun; 10(6):. PubMed ID: 34204736
[TBL] [Abstract][Full Text] [Related]
2. Identification of nephronectin as a new target for IGF1 action.
Sarfstein R; Lapkina-Gendler L; Nagaraj K; Laron Z; Werner H
Eur J Cancer; 2020 Dec; 141():115-127. PubMed ID: 33130549
[TBL] [Abstract][Full Text] [Related]
3. Identification of signaling pathways associated with cancer protection in Laron syndrome.
Lapkina-Gendler L; Rotem I; Pasmanik-Chor M; Gurwitz D; Sarfstein R; Laron Z; Werner H
Endocr Relat Cancer; 2016 May; 23(5):399-410. PubMed ID: 27090428
[TBL] [Abstract][Full Text] [Related]
4. Identification of UDP-Glucuronosyltransferase 2B15 (UGT2B15) as a Target for IGF1 and Insulin Action.
Sarfstein R; Nagaraj K; Parikh S; Levy C; Laron Z; Benayahu D; Werner H
Cells; 2022 May; 11(10):. PubMed ID: 35626664
[TBL] [Abstract][Full Text] [Related]
5. Identification of ZYG11A as a candidate IGF1-dependent proto-oncogene in endometrial cancer.
Achlaug L; Sarfstein R; Nagaraj K; Lapkina-Gendler L; Bruchim I; Dixit M; Laron Z; Yakar S; Werner H
Oncotarget; 2019 Jul; 10(43):4437-4448. PubMed ID: 31320996
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA 132-3p Is Upregulated in Laron Syndrome Patients and Controls Longevity Gene Expression.
Yaron-Saminsky D; Nagaraj K; Sarfstein R; Laron Z; Pasmanik-Chor M; Werner H
Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769292
[TBL] [Abstract][Full Text] [Related]
7. Identification of thioredoxin-interacting protein (TXNIP) as a downstream target for IGF1 action.
Nagaraj K; Lapkina-Gendler L; Sarfstein R; Gurwitz D; Pasmanik-Chor M; Laron Z; Yakar S; Werner H
Proc Natl Acad Sci U S A; 2018 Jan; 115(5):1045-1050. PubMed ID: 29339473
[TBL] [Abstract][Full Text] [Related]
8. Laron Syndrome Research Paves the Way for New Insights in Oncological Investigation.
Werner H; Sarfstein R; Nagaraj K; Laron Z
Cells; 2020 Nov; 9(11):. PubMed ID: 33182502
[TBL] [Abstract][Full Text] [Related]
9. Metformin downregulates the insulin/IGF-I signaling pathway and inhibits different uterine serous carcinoma (USC) cells proliferation and migration in p53-dependent or -independent manners.
Sarfstein R; Friedman Y; Attias-Geva Z; Fishman A; Bruchim I; Werner H
PLoS One; 2013; 8(4):e61537. PubMed ID: 23620761
[TBL] [Abstract][Full Text] [Related]
10. Congenital IGF-1 deficiency protects from cancer: lessons from Laron syndrome.
Laron Z; Werner H
Endocr Relat Cancer; 2023 Sep; 30(9):. PubMed ID: 37343154
[TBL] [Abstract][Full Text] [Related]
11. Long-Term IGF1 Stimulation Leads to Cellular Senescence via Functional Interaction with the Thioredoxin-Interacting Protein, TXNIP.
Nagaraj K; Sarfstein R; Laron Z; Werner H
Cells; 2022 Oct; 11(20):. PubMed ID: 36291127
[TBL] [Abstract][Full Text] [Related]
12. Genome-Wide Profiling of Laron Syndrome Patients Identifies Novel Cancer Protection Pathways.
Werner H; Lapkina-Gendler L; Achlaug L; Nagaraj K; Somri L; Yaron-Saminsky D; Pasmanik-Chor M; Sarfstein R; Laron Z; Yakar S
Cells; 2019 Jun; 8(6):. PubMed ID: 31208077
[TBL] [Abstract][Full Text] [Related]
13. Growth hormone receptor-deficient pigs resemble the pathophysiology of human Laron syndrome and reveal altered activation of signaling cascades in the liver.
Hinrichs A; Kessler B; Kurome M; Blutke A; Kemter E; Bernau M; Scholz AM; Rathkolb B; Renner S; Bultmann S; Leonhardt H; de Angelis MH; Nagashima H; Hoeflich A; Blum WF; Bidlingmaier M; Wanke R; Dahlhoff M; Wolf E
Mol Metab; 2018 May; 11():113-128. PubMed ID: 29678421
[TBL] [Abstract][Full Text] [Related]
14. Differential expression of IGFBPs in Laron syndrome-derived lymphoblastoid cell lines: Potential correlation with reduced cancer incidence.
Somri L; Sarfstein R; Lapkina-Gendler L; Nagaraj K; Laron Z; Bach LA; Werner H
Growth Horm IGF Res; 2018 Apr; 39():6-12. PubMed ID: 29208357
[TBL] [Abstract][Full Text] [Related]
15. Insulin-like growth factors and aging: lessons from Laron syndrome.
Werner H; Laron Z
Front Endocrinol (Lausanne); 2023; 14():1291812. PubMed ID: 37941907
[TBL] [Abstract][Full Text] [Related]
16. IGF1/IGF1R and microRNA let-7e down-regulate each other and modulate proliferation and migration of colorectal cancer cells.
Li Z; Pan W; Shen Y; Chen Z; Zhang L; Zhang Y; Luo Q; Ying X
Cell Cycle; 2018; 17(10):1212-1219. PubMed ID: 29886785
[TBL] [Abstract][Full Text] [Related]
17. The intrahepatic biliary epithelium is a target of the growth hormone/insulin-like growth factor 1 axis.
Alvaro D; Metalli VD; Alpini G; Onori P; Franchitto A; Barbaro B; Glaser SS; Francis H; Cantafora A; Blotta I; Attili AF; Gaudio E
J Hepatol; 2005 Nov; 43(5):875-83. PubMed ID: 16083987
[TBL] [Abstract][Full Text] [Related]
18. Upregulation of IRS1 Enhances IGF1 Response in Y537S and D538G ESR1 Mutant Breast Cancer Cells.
Li Z; Levine KM; Bahreini A; Wang P; Chu D; Park BH; Oesterreich S; Lee AV
Endocrinology; 2018 Jan; 159(1):285-296. PubMed ID: 29029116
[TBL] [Abstract][Full Text] [Related]
19. An integrin binding-defective mutant of insulin-like growth factor-1 (R36E/R37E IGF1) acts as a dominant-negative antagonist of the IGF1 receptor (IGF1R) and suppresses tumorigenesis but still binds to IGF1R.
Fujita M; Ieguchi K; Cedano-Prieto DM; Fong A; Wilkerson C; Chen JQ; Wu M; Lo SH; Cheung AT; Wilson MD; Cardiff RD; Borowsky AD; Takada YK; Takada Y
J Biol Chem; 2013 Jul; 288(27):19593-603. PubMed ID: 23696648
[TBL] [Abstract][Full Text] [Related]
20. Targeting the E3 ligase NEDD4 as a novel therapeutic strategy for IGF1 signal pathway-driven gastric cancer.
Wang K; Yu Y; Wang W; Jiang Y; Li Y; Jiang X; Qiao Y; Chen L; Zhao X; Liu J; Yang A; Li J; Zhang R
Oncogene; 2023 Mar; 42(14):1072-1087. PubMed ID: 36774408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
